20/20 BioLabs Q3 net loss widens 67% to $1.38 million; revenue falls 9% to $380,216
AIDX•20/20 BioLabs’ third-quarter 2026 net loss widened 67% year over year to $1.38 million, while revenue fell 9% to $380,216. Cash was $3.63 million at September 30, with no outstanding borrowings.
1. Quarterly results
20/20 BioLabs reported a third-quarter 2026 net loss of $1.38 million, up 67% year over year, and revenue of $380,216, down 9%. The revenue decline reflected the timing of state-funded firefighter cancer screening programs. Vermont executed a two-year firefighter screening contract, with testing expected to contribute revenue in Q4 2026.




